Skip to main content
OpenTrials
Completed

NCT Number: NCT00326612

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 week–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Primary Children's Medical Center

Salt Lake City, Utah, 84113, United States

About this study

Study Design: This is a prospective randomized controlled study.

Study Procedures: Parents/guardians will be provided with a stopwatch to help record seizure times on the "Parent Form". All parents of children who have a seizure lasting longer than five minutes will be randomized to treat their seizure with the study medication (either rectal diazepam or nasal midazolam). If a parent treats a child with a study medication for seizure activity they are required to call "911". Families will be instructed to only give one dose of the study medication. If the seizure persists, EMS may give a second medication and transport the patient to the ED as per their established protocol. All parents/guardians who participate in this study will be asked to fill out a "Pre-study Form" (to be filled out during enrollment into the study) and a "Parent Form" for every seizure that is treated with the study medication. They will be given a stamped returned envelope to return the questionnaire. Once the study medication is used once, they will be done with the study. Any further need of home rescue medications to treat acute seizure activity will be coordinated by their neurologist. If questions arise, a study coordinator will be available by phone. In addition, parents/guardians will be contacted by phone every two months and questioned at clinic visits to audit compliance of reporting of seizures/hospitalizations, adverse events and answer any questions that arise. The study packet also instructs all families to call the study coordinator immediately if any expected or unexpected complication occurs. The study coordinator will be called on all ED visits and hospitalizations. We will then collect and analyze adverse events to compare them between the two groups. Any ER visit or hospitalization will be considered an adverse event and will be analyzed for its relationship to the seizure or medication. All adverse events will be reported to the IRB. See Table 1 for doses for the two study medications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children seventeen years and under will be identified through a Pediatric Neurology clinic at Primary Children's Medical Center,
  • Known seizure disorder, AND
  • Either have or will be prescribed a rescue anti-epileptic (rectal diazepam, or Diastat) for home use by their neurologist.

Exclusion criteria

  • The neurologist does not prescribe a rescue medication for home use,
  • 18 years of age or older,
  • They have absence seizures, OR
  • They have been prescribed lorazepam for home use for seizure activity.

Treatment and study plan

midazolam

Drug

Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.

Other names: Diastat

Diazepam

Drug

Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.

Other names: Versed

Primary outcomes

  1. Length of Seizure After Study Medication Administration

    Time frame: 24 hours

    Length of seizure.

Secondary outcomes

  1. Respiratory Depression Requiring Intubation

    Time frame: 24 hours

    Respiratory depression was defined as intubation at Emergency Department discharge.

  2. Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours

    Time frame: 24 hours

  3. Number of Patients Needed to be Seen or Treated in the Emergency Department for Their Seizure and Use of Study Medication.

    Time frame: 24 hours

  4. Number of Patients That Were Admitted to the Hospital After Their Seizure and Use of Study Medication.

    Time frame: 24 hours

  5. Number of Patients Who Had a Repeat Seizure Within 12 Hours After Their Seizure Who Used Study Medication

    Time frame: 12 hours

  6. Respiratory Depression Requiring Oxygen at Discharge From the Emergency Department.

    Time frame: 24 hours

    Respiratory depression was defined as requiring oxygen at discharge from the Emergency Department.

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Collaborators

  • Primary Children's Hospital

Registry information

Official study title

Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
May 17, 2006
Registry last updated
Oct 26, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.